Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists.
Neuropeptide FF (NPFF) belongs to an opioid-modulatory system including two precursors (pro-NPFF(A) and pro-NPFF(B)) and two G-protein coupled receptors (NPFF(1) and NPFF(2)). The pharmacological and functional profiles of human NPFF(1) and NPFF(2) receptors expressed in Chinese hamster ovary (CHO) cells were compared by determining the affinity of several peptides derived from both NPFF precursors and by measuring their abilities to inhibit forskolin-induced cAMP accumulation. Each NPFF receptor recognizes peptides from both precursors with nanomolar affinities, however, with a slight preference of pro-NPFF(A) peptides for NPFF(2) receptors and of pro-NPFF(B) peptides for NPFF(1) receptors. BIBP3226 ((R)-N(2)-(diphenylacetyl)-N-[(4-hydroxyphenyl)-methyl]-argininamide) and BIBO3304 ((R)-N(2)-(diphenylacetyl)-N-[4-(aminocarbonylaminomethyl)-benzyl]-argininamide trifluoroacetate), two selective neuropeptide Y (NPY) Y(1) receptor antagonists, display relative high affinities for NPFF receptors and exhibit antagonist properties towards hNPFF(1) receptors. The structural determinants responsible for binding of these molecules to NPFF receptors were investigated and led to the synthesis of hNPFF(1) receptor antagonists with affinities from 40 to 80 nM. Our results demonstrate differences in pharmacological characteristics between NPFF(1) and NPFF(2) receptors and the feasibility of subtype-selective antagonists.
Mollereau
Catherine
C
Institut de Pharmacologie et de Biologie Structurale (CNRS, UMR5089), 205 route de Narbonne, 31077 Toulouse cedex 04, France. catherine.mollereau-manaute@ipbs.fr
Mazarguil
Honoré
H
Marcus
Delphine
D
Quelven
Isabelle
I
Kotani
Masato
M
Lannoy
Vincent
V
Dumont
Yvan
Y
Quirion
Rémi
R
Detheux
Michel
M
Parmentier
Marc
M
Zajac
Jean-Marie
JM
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D018013:Receptors, Neuropeptide / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D013329:Structure-Activity Relationship; D014162:Transfection
C092926:BIBP 3226; D018013:Receptors, Neuropeptide; C083929:neuropeptide FF receptor; D001120:Arginine; C117416:BIBO 3304